论文部分内容阅读
据统计在美国近10年来垂体催乳激素瘤的年发病率为每10万妇女约1～7名。由于新诊断技术的确切有效,尤以催乳激素测定和蝶鞍×线断层摄影使多数病例得以作出诊断。可是垂体腺癌的病因学尚未阐明,其它因素如避孕药等也可能和发病有关。催乳激素瘤病例显著增加似乎与近20年间较大量应用口服避孕药相伴随。在人类,雌激素有促进催乳激素分泌的功能,因此曾反复提出如下的问题:口服避孕药是否能触发已存在的或潜藏的微腺瘤的发
According to statistics, in the United States in the past 10 years, the annual incidence of pituitary prolactinoma was about 1 to 7 per 100,000 women. Due to the exact effectiveness of the new diagnostic technique, most cases are diagnosed with prolactin and sellar x-ray tomography. However, the etiology of pituitary adenocarcinoma has not been elucidated, other factors such as contraceptives may also be related to the incidence. A significant increase in prolactinoma cases appears to be associated with the greater use of oral contraceptives in the past 20 years. In humans, estrogen has the role of prolactin secretion, and has repeatedly asked the question: whether oral contraceptives can trigger the presence of existing or latent micro-adenoma